Latest Atlantic Pharmaceuticals Inc. Stories
ATLANTA, May 20, 2013 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company that has developed and is commercializing a unique technology to deter prescription drug abuse today announced that its founder and President, Anthony Soscia, has been chosen as a finalist for the Atlanta Business Chronicle's Health-Care Heroes Awards. The awards are presented annually by the Atlanta Business Chronicle to honor individuals and organizations demonstrating excellence...
ATLANTA, Dec. 20, 2012 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that new patents have been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper-resistant SMART/Script(TM) drug delivery platform. U.S. Patent Nos. 8,187,636 and 8,349,362 contain claims that cover Atlantic's proprietary tamper-resistant platform which are designed to resist dose dumping of orally delivered opioids and may sequester and...
WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) today honored Atlantic Pharmaceuticals' SMART/Script as one of its "Top 5 Technologies To Reduce Prescription Drug Abuse." Still in investigational stages, the SMART/Script technology is intended to deliver immediate- and extended-release opioid medications in a tamper-resistant form. If a medication formulated with SMART/Script were crushed or chewed, the SMART/Script...
ATLANTA, June 23 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has completed a pre-investigational new drug (PIND) meeting with the Food and Drug Administration (FDA) for guidance on a mutually acceptable regulatory pathway for submission of an abuse deterrent immediate release oxycodone. Atlantic's proprietary oral delivery technology Smart/Script(TM) is the basis of the abuse deterrent characteristics of the product. For the...
